Discovering The Potential of IGHV3-48 as A Drug Target Or Biomarker

Target Name: IGHV3-48

NCBI ID: G28424

IGHV3-48

Other Name(s): IGHV348 | immunoglobulin heavy variable 3-48 | VH | Immunoglobulin heavy variable 3-48

Discovering The Potential of IGHV3-48 as A Drug Target Or Biomarker

IGHV3-48 (IGHV348) is a type of gene that encodes for the interleukin-gene-variable subunit 3 (IL-3) receptor. This receptor is a protein that is expressed in various tissues throughout the body, including bone marrow, lymphoid organs, and skin. It plays a crucial role in the regulation of immune responses and is involved in the development of autoimmune diseases.

One of the unique aspects of IGHV3-48 is its location in the genome. It is located on chromosome 12, which is one of the most highly conserved regions of the human genome. This makes IGHV3-48 an attractive candidate for drug targeting, as any changes in the gene's expression or function are likely to be well-preserved.

While IGHV3-48 has been identified as a potential drug target, more research is needed to determine its exact role in the immune system and to identify potential drug approaches. One possible approach is to target IGHV3-48 directly with small molecules or antibodies that can modulate its activity.

Another approach to studying IGHV3-48 is to use it as a biomarker to test for the presence of disease. For example, researchers can use IGHV3-48 as a marker to track the progress of an immune response in response to a particular treatment. This can help to determine whether the treatment is having the desired effect and to identify potential drug targets that may be effective in treating the disease.

In addition to its potential as a drug target, IGHV3-48 is also a promising biomarker for certain types of cancer. For example, studies have shown that IGHV3-48 is often expressed in various types of cancer, including leukemia, melanoma, and breast cancer. This makes IGHV3-48 an attractive candidate for use as a biomarker for cancer detection and treatment.

Overall, IGHV3-48 is a fascinating gene that has the potential to be a drug target or biomarker. Further research is needed to fully understand its role in the immune system and to develop effective drug approaches. If its potential is confirmed, IGHV3-48 could be a valuable tool for the treatment of a range of diseases.

Protein Name: Immunoglobulin Heavy Variable 3-48

Functions: V region of the variable domain of immunoglobulin heavy chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

The "IGHV3-48 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHV3-48 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets